KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $3.3 million.

  • Halozyme Therapeutics' Depreciation & Amortization (CF) rose 2267.66% to $3.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.4 million, marking a year-over-year increase of 1032.61%. This contributed to the annual value of $11.4 million for FY2025, which is 1067.96% up from last year.
  • As of Q4 2025, Halozyme Therapeutics' Depreciation & Amortization (CF) stood at $3.3 million, which was up 2267.66% from $2.7 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) registered a high of $3.3 million during Q4 2025, and its lowest value of $700000.0 during Q3 2021.
  • For the 5-year period, Halozyme Therapeutics' Depreciation & Amortization (CF) averaged around $2.1 million, with its median value being $2.6 million (2024).
  • In the last 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) plummeted by 1800.0% in 2021 and then soared by 23105.67% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $776000.0 in 2021, then surged by 231.06% to $2.6 million in 2022, then grew by 12.88% to $2.9 million in 2023, then dropped by 7.24% to $2.7 million in 2024, then grew by 22.68% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q4 2025, $2.7 million for Q3 2025, and $2.7 million during Q2 2025.